STOCK TITAN

PacBio to Present at Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference:

  • 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm Eastern Time (9:00 am Pacific Time)

The live webcast can be accessed at the company’s investors page at https://investor.pacificbiosciences.com . A replay of the webcast will be available for at least 30 days following the presentation.

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information please visit www.pacb.com and follow @PacBio.

Contacts

Investors:
Todd Friedman
650.521.8450
ir@pacb.com

Media:
Kathy Lynch
pr@pacb.com


Pacific Biosciences of California, Inc.

NASDAQ:PACB

PACB Rankings

PACB Latest News

PACB Stock Data

479.32M
266.44M
2.8%
101.74%
18.31%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
MENLO PARK

About PACB

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.